NBM-200 Clinical Study in Blood Donation Setting
The NBM-200 is a portable Hemoglobin and oximetry monitor, based on occlusion spectroscopy technology, for non-invasive spot checking of hemoglobin (Hb), estimated Hematocrit (Hct), SpO2 and pulse rate.
The NBM-200 includes a reusable ring-shaped sensor probe that fits on the patient's finger, and a portable desktop monitor that calculates and displays the measurement result.
The sensor probe consists of a multi-wavelength optical measuring system and inflatable cuff employing pneumatic tissue manipulation. Blood flow in the finger can be briefly occluded and the resulting changes in its optical behavior are analyzed to provide accurate measurements of Hb.
研究概览
详细说明
The proposed study plan will support a 510(k) submission for the non-invasive NBM-200 system with a blood bank indication. In accordance with the agency's suggestion, OrSense plans to use as a predicate an FDA-cleared blood analyzer with a hemoglobin test method that is traceable to the cyanmethemoglobin method or that was standardized and calibrated using the International Council for Standardization in Hematology (ICSH) hemoglobin standard, e.g., the HemoCue-301 or EKF's Hemo Control Hemoglobin Measurement System. OrSense further plans to use the cleared NBM-200 (K142209) as a reference device. Clinical data will be collected in a blood donor population using 3 methods to check hemoglobin (Hb): (1) the non-invasive NBM-200 system; (2) a point-of-care device based on finger sticks that is FDA-cleared for use in blood banks, such as the HemoCue or EKF device; and (3) a laboratory analyzer based on venous blood samples.
Participants will be recruited via email and during their visit to the designated donor rooms.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Florida
-
Palm Harbor、Florida、美国、34684
- Palm Harbor Donor Center
-
Saint Petersburg、Florida、美国、33716
- OneBlood St. Pete Main Donor Center
-
Tampa、Florida、美国、33624
- Tampa- Dale Mabry OneBlood Donor Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Regular donors and volunteers
Exclusion Criteria:
- Pregnancy
学习计划
研究是如何设计的？
设计细节
- 主要用途：诊断
- 分配：非随机化
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他：Comparison
Comparison study: The participants (at least 300) will be tested once with each of the 3 devices. First, a measurement with the NBM-200 will be performed according to the user manual. The best finger to use, in order of preference: 1) right thumb 2) left thumb 3) right index 4) left index. The POC capillary test will follow the NBM-200 test, and the venous test will be performed last. A venous blood sample will be obtained from all participants in the comparison study, even if a subject is designated to donate and is deferred from donation because of low hemoglobin. |
Finger Prick and Venipuncture
其他名称：
|
|
其他：Precision A & B
Precision study:
A laboratory test with venous blood is not required for participants in the precision study. |
Finger Prick and Venipuncture
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Bias
大体时间：24 hours
|
The mean bias between the NBM-200 and HemoCue readings and the laboratory reference
|
24 hours
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- OrSense-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
血红蛋白H的临床试验
-
Akdeniz UniversityThe Scientific and Technological Research Council of Turkey完全的
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)招聘中难治性 MSI - H 实体瘤 PD-(L) 1 治疗之前 | MSI-H 肿瘤美国
-
Servier Bio-Innovation LLCMerck Sharp & Dohme LLC; Institut de Recherches Internationales Servier尚未招聘MSI-H/dMMR 胃食管结合部癌 | MSI-H/dMMR 胃癌
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.未知
-
Yonsei UniversityMerck KGaA, Darmstadt, Germany主动，不招人
-
ImmuneOncia Therapeutics Inc.尚未招聘TMB-H | 组织学或细胞学证明的转移性或局部晚期实体瘤
NBM-200的临床试验
-
Helen M. Bronte-StewartNational Institute of Neurological Disorders and Stroke (NINDS)招聘中
-
Boston Scientific CorporationICON plc完全的心脏衰竭西班牙, 比利时, 荷兰, 香港, 意大利, 法国, 芬兰, 瑞士, 以色列, 德国, 英国, 哥伦比亚, 新加坡, 丹麦, 葡萄牙, 日本, 奥地利, 爱尔兰
-
GlaxoSmithKline完全的哮喘美国, 澳大利亚, 德国, 俄罗斯联邦, 保加利亚, 加拿大, 智利, 秘鲁, 菲律宾, 南非, 泰国, 墨西哥, 以色列, 乌克兰, 新西兰, 克罗地亚